Medical Research Council-ko ikertzaileekin lankidetzan egindako argitalpenak (14)

2021

  1. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

2019

  1. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

    JAMA network open, Vol. 2, Núm. 9, pp. e1911750

  2. Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism

    Movement Disorders, Vol. 34, Núm. 10, pp. 1547-1561

2017

  1. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

    Annals of Oncology, Vol. 28, Núm. 4, pp. 711-717

2016

  1. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals

    Medicine (United States), Vol. 95, Núm. 41

2014

  1. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis

    Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. The epidemiology of anaphylaxis in Europe: A systematic review

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 68, Núm. 11, pp. 1353-1361

2011

  1. Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial

    AIDS

  2. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer

    International Journal of Gynecological Cancer

2008

  1. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up

    Journal of Infectious Diseases, Vol. 197, Núm. 8, pp. 1145-1155

  2. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study

    Journal of Infectious Diseases, Vol. 197, Núm. 8, pp. 1133-1144

  3. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial

    Annals of Internal Medicine, Vol. 149, Núm. 5, pp. 289-299

2001

  1. Duration of ruptured membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies

    AIDS, Vol. 15, Núm. 3, pp. 357-368